Form 4: Teva Chief Accounting Officer's Equity Transactions

Amir Weiss, Teva's Chief Accounting Officer, reported the vesting of restricted share units and a new RSU grant on March 4, 2026.

Summary

• Amir Weiss, Teva Pharmaceutical Industries Ltd.'s Chief Accounting Officer, reported changes in his beneficial ownership of company securities.
• On March 4, 2026, 10,679 restricted share units (RSUs) granted on March 4, 2022, vested and were converted into 10,679 ordinary shares.
• Also on March 4, 2026, 5,650 restricted share units (RSUs) granted on March 4, 2024, vested and were converted into 5,650 ordinary shares.
• Following these conversions, Weiss's direct beneficial ownership of ordinary shares increased to 27,158.
• Additionally, on March 4, 2026, Weiss was granted 11,280 new restricted share units, which will vest in four equal annual installments of 2,820 units starting March 4, 2027, through March 4, 2030.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and continued alignment of management interests with shareholders through long-term equity grants.

Positives

• The vesting of 16,329 restricted share units (10,679 + 5,650) indicates the successful completion of performance or time-based conditions for equity compensation.
• A new grant of 11,280 restricted share units demonstrates continued equity-based compensation for the Chief Accounting Officer, aligning his interests with long-term shareholder value.

Future Outlook

The grant of new restricted share units to the Chief Accounting Officer, vesting through March 4, 2030, indicates a long-term incentive structure for key management.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through restricted share units, is a standard practice across the pharmaceutical industry to attract, retain, and incentivize key executives. This filing reflects a routine compensation event for a senior officer at Teva, consistent with broader industry trends in executive remuneration.

Related Party Transactions

• The reported transactions involve the Chief Accounting Officer, Amir Weiss, acquiring and being granted equity compensation from Teva Pharmaceutical Industries Ltd., which are inherently related-party transactions as part of executive remuneration.

Stakeholder Impact

• Shareholders: The vesting and new grant of equity compensation align the Chief Accounting Officer's interests with long-term shareholder value.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• Future vesting of 5,650 restricted share units on March 4, 2027, and March 4, 2028, from the March 4, 2024 grant.
• Future vesting of 2,820 restricted share units annually from March 4, 2027, through March 4, 2030, from the March 4, 2026 grant.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation events for a senior executive, including the vesting of previously granted restricted share units and a new grant. Such transactions are standard practice for executive remuneration and do not provide new fundamental information that would warrant a change in investment recommendation. The filing indicates ongoing executive alignment with company performance but does not offer insights into operational or financial performance that would drive a 'buy' or 'sell' decision.

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, Insider Trading, Restricted Share Units, RSU, Equity Compensation, Amir Weiss, Chief Accounting Officer, Beneficial Ownership, Rule 10b5-1